• 
  Thierry Lebret, Xavier Paoletti, Géraldine Pignot, Mathieu Roumiguié, Marc C. Colombel, et al.. Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial. World Journal of Urology, 2023, 41, pp.2381-2388. ⟨10.1007/s00345-023-04519-4⟩. ⟨hal-04195182⟩
• 
  Jordi Remon, Nicolas Girard, Silvia Novello, Javier de Castro, Laurence Bigay-Game, et al.. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer, 2021, ⟨10.1016/j.cllc.2021.07.008⟩. ⟨hal-03524401⟩
• 
  Guilhem Roubaud, M. Özgüroğlu, Nicolas Penel, N. Matsubara, N. Mehra, et al.. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.. European Journal of Cancer, 2022, European Journal of Cancer, 170, pp.73-84. ⟨10.1016/j.ejca.2022.04.016⟩. ⟨hal-04568938⟩
• 
  Capucine Baldini, E. Charton, E. Schultz, L. Auroy, A. Italiano, et al.. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. ESMO Open, 2022, European Society for Medical Oncology, 7, pp.100468. ⟨10.1016/j.esmoop.2022.100468⟩. ⟨hal-04567217⟩
• 
  Kevin Atsou, Anne Auperin, Joël Guigay, Sébastien Salas, Sébastien Benzekry. Tumor kinetics modeling outperforms best overall response for prediction of survival in head and neck squamous cell carcinoma. 2024. ⟨hal-04558029⟩
• 
  Mark van Barele, Delal Akdeniz, Bernadette a M Heemskerk-Gerritsen, Nadine Andrieu, Catherine Noguès, et al.. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation. JNCI: Journal of the National Cancer Institute, 2024, 115, pp.1318 - 1328. ⟨10.1093/jnci/djad116⟩. ⟨inserm-04545755⟩
• 
  Antoine Verger, T. Horowitz, F. Le Jeune, C. Prunier-Aesh, S. Querellou, et al.. Clinical authorization of amyloid PET in France: Towards a more precise diagnosis of Alzheimer's disease. Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique, 2023, 47 (4), pp.175-178. ⟨10.1016/j.mednuc.2023.03.002⟩. ⟨hal-04415555⟩
• 
  Pauline Rimmelé, Michela Esposito, Laure Delestré, Jean-Hugues Guervilly, Maya Ridinger-Saison, et al.. The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemia. Oncotarget, 2017, 8 (23), ⟨10.18632/oncotarget.16183⟩. ⟨hal-02424493⟩
• 
  Carolina Velazquez, Esin Orhan, Imene Tabet, Lise Fenou, Béatrice Orsetti, et al.. BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib. Frontiers in Oncology, 2023, 13, pp.1125021. ⟨10.3389/fonc.2023.1125021⟩. ⟨hal-04275543⟩
• 
  Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
• 
  Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. Thyroid, 2023, 33 (9), pp.1124-1129. ⟨10.1089/thy.2023.0240⟩. ⟨inserm-04527070⟩
• 
  Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, et al.. Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study. Molecular Cancer, 2023, 22 (1), pp.176. ⟨10.1186/s12943-023-01878-9⟩. ⟨inserm-04521346⟩
• 
  Alicia Rovó, Luuk Gras, Brian Piepenbroek, Nicolaus Kröger, H. Christian Reinhardt, et al.. Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.. American Journal of Hematology, 2023, American Journal of Hematology, ⟨10.1002/ajh.27150⟩. ⟨hal-04510879⟩
• 
  Sebastien Salas, Guillaume Economos, Damien Hugues, Elise Gilbert, Dominique Gracia, et al.. Legalisation of euthanasia and assisted suicide: advanced cancer patient opinions – cross-sectional multicentre study. BMJ Palliative and supportive care, 2023, 13 (e3), pp.e1335-e1341. ⟨10.1136/spcare-2022-004134⟩. ⟨hal-04382168⟩
• 
  Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, et al.. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. npj Breast Cancer, 2017, 3 (1), pp.4. ⟨10.1038/s41523-017-0005-y⟩. ⟨cea-04501580⟩
• 
  Elsa Nigon, Claudia Lefeuvre-Plesse, Alejandra Martinez, Céline Chauleur, Alain Lortholary, et al.. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network. Journal of Translational Medicine, 2023, 21 (1), pp.408. ⟨10.1186/s12967-023-04264-7⟩. ⟨hal-04390892⟩
• 
  Alice Mogenet, Pascal Finetti, Emilie Denicolai, Laurent Greillier, Pascaline Boudou-Rouquette, et al.. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer. Journal of Translational Medicine, 2023, 21 (1), pp.637. ⟨10.1186/s12967-023-04463-2⟩. ⟨hal-04390901⟩
• 
  Rossella Libé, Magalie Haissaguerre, Karine Renaudin, Matthieu Faron, Myriam Decaussin-Petrucci, et al.. Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study. Bulletin du Cancer, 2023, 110 (10), pp.707 - 730. ⟨10.1016/j.bulcan.2023.03.015⟩. ⟨inserm-04500838⟩
• 
  Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, et al.. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology, 2023, 83 (3), pp.267 - 293. ⟨10.1016/j.eururo.2022.11.002⟩. ⟨inserm-04494406⟩
• 
  Klaus Hirschbühl, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Jean Henri Bourhis, et al.. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.. Bone Marrow Transplantation, 2023, Bone Marrow Transplantation, ⟨10.1038/s41409-023-01966-w⟩. ⟨hal-04487889⟩

320

374